Effects of chromium picolinate as an adjuvant on HbA1c levels in diabetic patients, and on eGFR and serum creatinine levels in diabetes induced renal impaired patients.

A 45-day prospective randomized clinical trial investigated the effects of chromium picolinate supplementation in diabetic patients and those with diabetes-induced renal impairment. With 100 participants evenly splited between control and supplemented groups, the study showed significant improvements in glycemic control and diabetes-induced renal impairment in the chromium group. This group exhibited significant reductions in HbA1c and RBS levels, along with enhanced renal function indicated by reduced serum creatinine and increased eGFR. Additionally, chromium supplementation positively impacted HDL levels and showed potential in reducing LDL levels, suggesting implications for cardiovascular health. The study also noted benefits in weight management and blood pressure, attributing these effects to improved insulin sensitivity, glucose metabolism, and reduced renin-angiotensin system activity. The control group did not receive a placebo, which could introduce a placebo effect in the chromium-supplemented group, potentially skewing the results. The study period was 45 days, which might not be long enough to observe the long-term effects or potential side effects of chromium picolinate supplementation. Some benefits or risks might only manifest over extended periods. It is recommended to do future studies with more extended durations and different dosages to further validate these findings and explore long-term implications.